Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillance
SARS-CoV-2 anti-spike IgG production and protection from severe respiratory illness should be explored in greater depth after COVID-19 booster vaccination. This longitudinal observational retrospective study investigated the anti-spike IgG response elicited by the first, second and booster doses of...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-08-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2258632 |
| _version_ | 1797633627401486336 |
|---|---|
| author | Vanessa De Pace Bianca Bruzzone Valentina Ricucci Nicola Calcavecchia Giulia Guarona Irene Giberti Elisabetta Costa Matilde Ogliastro Barbara Galano Nicola Nigro Daniele Murgia Luca Nanni Andrea Orsi |
| author_facet | Vanessa De Pace Bianca Bruzzone Valentina Ricucci Nicola Calcavecchia Giulia Guarona Irene Giberti Elisabetta Costa Matilde Ogliastro Barbara Galano Nicola Nigro Daniele Murgia Luca Nanni Andrea Orsi |
| author_sort | Vanessa De Pace |
| collection | DOAJ |
| description | SARS-CoV-2 anti-spike IgG production and protection from severe respiratory illness should be explored in greater depth after COVID-19 booster vaccination. This longitudinal observational retrospective study investigated the anti-spike IgG response elicited by the first, second and booster doses of BNT162b2 mRNA vaccine in healthcare workers (HCW) at San Martino IRCCS Policlinico Hospital (Genoa) up to the 12th month. Sequential blood sampling was performed at T0 (prior to vaccination), T1 (21 days after the 1st dose of vaccine), T2, T3, T4, T5, T6 (7 days and 1, 3, 6 and 9 months after the 2nd dose, respectively), T7 and T8 (1 and 3 months after a booster dose). A SARS-CoV-2 IgG panel (Bio-Rad, Marnes-la-Coquette, France) was used to determine levels of receptor-binding domain (RBD), spike-1 (S1), spike-2 and nucleocapsid structural proteins of SARS-CoV-2. In the 51 HCWs evaluated, seroprevalence was 96% (49/51) at T1 and 100% (51/51) from T2 to T5 for RBD and S1. At T6, only one HCW was negative. T2 [RBD = 2945 (IQR:1693–5364); S1 = 1574 (IQR:833–3256) U/mL], and T7 [RBD = 8204 (IQR:4129–11,912); S1 = 4124 (IQR:2124–6326) U/mL] were characterized by the highest antibody values. Significant humoral increases in RBD and S1 were documented at T7 and T8 compared to T2 and T4, respectively (p-value < .001). Following vaccination with BNT162b2 and a booster dose in the 9th month, naïve and healthy subjects show high antibody titers up to 12 months and a protective humoral response against COVID-19 disease lasting up to 20 months after the last booster. |
| first_indexed | 2024-03-11T11:57:35Z |
| format | Article |
| id | doaj.art-2cadcec41cc4461c9d6a378b15abfbee |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T11:57:35Z |
| publishDate | 2023-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-2cadcec41cc4461c9d6a378b15abfbee2023-11-08T12:12:53ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-08-0119210.1080/21645515.2023.22586322258632Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillanceVanessa De Pace0Bianca Bruzzone1Valentina Ricucci2Nicola Calcavecchia3Giulia Guarona4Irene Giberti5Elisabetta Costa6Matilde Ogliastro7Barbara Galano8Nicola Nigro9Daniele Murgia10Luca Nanni11Andrea Orsi12San Martino Policlinico Hospital - IRCCS for Oncology and NeurosciencesSan Martino Policlinico Hospital - IRCCS for Oncology and NeurosciencesSan Martino Policlinico Hospital - IRCCS for Oncology and NeurosciencesUniversity of GenoaUniversity of GenoaUniversity of GenoaUniversity of GenoaUniversity of GenoaSan Martino Policlinico Hospital - IRCCS for Oncology and NeurosciencesSan Martino Policlinico Hospital - IRCCS for Oncology and NeurosciencesSan Martino Policlinico Hospital - IRCCS for Oncology and NeurosciencesSan Martino Policlinico Hospital - IRCCS for Oncology and NeurosciencesSan Martino Policlinico Hospital - IRCCS for Oncology and NeurosciencesSARS-CoV-2 anti-spike IgG production and protection from severe respiratory illness should be explored in greater depth after COVID-19 booster vaccination. This longitudinal observational retrospective study investigated the anti-spike IgG response elicited by the first, second and booster doses of BNT162b2 mRNA vaccine in healthcare workers (HCW) at San Martino IRCCS Policlinico Hospital (Genoa) up to the 12th month. Sequential blood sampling was performed at T0 (prior to vaccination), T1 (21 days after the 1st dose of vaccine), T2, T3, T4, T5, T6 (7 days and 1, 3, 6 and 9 months after the 2nd dose, respectively), T7 and T8 (1 and 3 months after a booster dose). A SARS-CoV-2 IgG panel (Bio-Rad, Marnes-la-Coquette, France) was used to determine levels of receptor-binding domain (RBD), spike-1 (S1), spike-2 and nucleocapsid structural proteins of SARS-CoV-2. In the 51 HCWs evaluated, seroprevalence was 96% (49/51) at T1 and 100% (51/51) from T2 to T5 for RBD and S1. At T6, only one HCW was negative. T2 [RBD = 2945 (IQR:1693–5364); S1 = 1574 (IQR:833–3256) U/mL], and T7 [RBD = 8204 (IQR:4129–11,912); S1 = 4124 (IQR:2124–6326) U/mL] were characterized by the highest antibody values. Significant humoral increases in RBD and S1 were documented at T7 and T8 compared to T2 and T4, respectively (p-value < .001). Following vaccination with BNT162b2 and a booster dose in the 9th month, naïve and healthy subjects show high antibody titers up to 12 months and a protective humoral response against COVID-19 disease lasting up to 20 months after the last booster.http://dx.doi.org/10.1080/21645515.2023.2258632sars-cov-2covid-19bnt162b2 vaccinehealthcare workersanti-spike igg seroprevalence |
| spellingShingle | Vanessa De Pace Bianca Bruzzone Valentina Ricucci Nicola Calcavecchia Giulia Guarona Irene Giberti Elisabetta Costa Matilde Ogliastro Barbara Galano Nicola Nigro Daniele Murgia Luca Nanni Andrea Orsi Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillance Human Vaccines & Immunotherapeutics sars-cov-2 covid-19 bnt162b2 vaccine healthcare workers anti-spike igg seroprevalence |
| title | Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillance |
| title_full | Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillance |
| title_fullStr | Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillance |
| title_full_unstemmed | Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillance |
| title_short | Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillance |
| title_sort | long follow up of bnt162b2 mrna vaccine in healthcare workers 2020 2022 a retrospective longitudinal sars cov 2 serological surveillance |
| topic | sars-cov-2 covid-19 bnt162b2 vaccine healthcare workers anti-spike igg seroprevalence |
| url | http://dx.doi.org/10.1080/21645515.2023.2258632 |
| work_keys_str_mv | AT vanessadepace longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT biancabruzzone longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT valentinaricucci longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT nicolacalcavecchia longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT giuliaguarona longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT irenegiberti longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT elisabettacosta longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT matildeogliastro longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT barbaragalano longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT nicolanigro longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT danielemurgia longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT lucananni longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance AT andreaorsi longfollowupofbnt162b2mrnavaccineinhealthcareworkers20202022aretrospectivelongitudinalsarscov2serologicalsurveillance |